Exemestane

Generic Name: Exemestane

Brand Names: Aromasin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄O_₂

CAS Number: 107868-30-4

Unique Ingredient Identifier: NY22HMQ4BX

Background: Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Indication: For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Associated Conditions: Stage I Breast Cancer, Refractory, advanced Breast cancer

Associated Therapies: -

Clinical Trials

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Phase 3

Completed

Conditions: Progression-free Survival

Interventions: Drug: fulvestrant
Drug: exemestane
Drug: anastrozole

First Posted Date: 2009-07-23

Last Posted Date: 2011-08-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 25

Registration Number: NCT00944918

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Exemestane
Drug: Cytoxan

First Posted Date: 2009-07-17

Last Posted Date: 2017-04-10

Lead Sponsor: Emory University

Target Recruit Count: 31

Registration Number: NCT00941330

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

The Impact of Obesity and Obesity Treatments on Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Exemestane
Drug: Avandamet

First Posted Date: 2009-07-07

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00933309

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Exemestane

First Posted Date: 2009-07-03

Last Posted Date: 2010-07-20

Lead Sponsor: Pfizer

Target Recruit Count: 451

Registration Number: NCT00932165

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Phase 1

Conditions: Breast Cancer

Interventions: Drug: exemestane
Other: placebo
Drug: sunitinib malate

First Posted Date: 2009-07-02

Last Posted Date: 2013-08-12

Lead Sponsor: Institut Català d'Oncologia

Target Recruit Count: 70

Registration Number: NCT00931450

Locations: 🇪🇸
Institut Catala D'Oncologia, l'Hospitalet de Llobregat, Spain

Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant

Phase 2

Completed

Conditions: Breast Neoplasms

First Posted Date: 2009-06-12

Last Posted Date: 2009-06-12

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 15

Registration Number: NCT00919399

Locations: 🇫🇷
CHU de Toulouse Rangueil, Toulouse, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Exemestane
Drug: Sutent

First Posted Date: 2009-05-20

Last Posted Date: 2020-07-24

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 4

Registration Number: NCT00905021

Locations: 🇺🇸
Baylor College of Medicine, Lester and Sue Smith Breast Center, Houston, Texas, United States

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Phase 3

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: letrozole
Drug: exemestane

First Posted Date: 2009-05-15

Last Posted Date: 2009-05-15

Lead Sponsor: Fudan University

Target Recruit Count: 540

Registration Number: NCT00902954

Locations: 🇨🇳
Jinsong Lu, Shanghai, Shanghai, China

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: tamoxifen citrate
Drug: anastrozole
Drug: exemestane
Drug: letrozole

First Posted Date: 2009-05-05

Last Posted Date: 2024-06-14

Lead Sponsor: Centre Oscar Lambret

Target Recruit Count: 44

Registration Number: NCT00893061

Locations: 🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷
Centre Eugene Marquis, Rennes, France
🇫🇷
Centre Oscar Lambret, Lille, France

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Everolimus
Drug: Everolimus Placebo
Drug: Exemestane

First Posted Date: 2009-03-18

Last Posted Date: 2017-05-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 724

Registration Number: NCT00863655

Locations: 🇺🇸
University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr., Dallas, Texas, United States
🇺🇸
Mercy Medical Center Medical Oncology & Hematology, Baltimore, Maryland, United States
🇺🇸
Crescent City Research Consortium, LLC Dept of Hem&Onc Specialist - 2, Metairie, Louisiana, United States

and more 61 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy